Plasma Dehydroepiandrosterone and Risk of Myocardial Infarction in Women

Overview

Journal Clin Chem

Publisher Oxford University Press

Specialty Biochemistry

Date 2008 May 3

PMID 18451313

Citations 10

Authors

John H Page

Jing Ma

Kathryn M Rexrode

Nader Rifai

JoAnn E Manson

Susan E Hankinson

Affiliations

Soon will be listed here.

Abstract

Background: In this study we prospectively evaluated the relationships between plasma concentrations of dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEA-S) and subsequent myocardial infarction in women.

Methods: Using case-control sampling, we selected participants from the Nurses' Health Study cohort. Blood samples were collected from 1989 to 1990 when the women were 43 to 69 years old. During follow-up through June 1998, 239 women were diagnosed with myocardial infarction (fatal and nonfatal). We matched cases 1:2 by age, cigarette smoking status, fasting status, and month of blood collection and used conditional logistic regression to adjust for potential confounders, including anthropometric factors and dietary intake.

Results: Baseline median (10th, 90th percentiles) concentrations of DHEA were 17.1 (4.3, 46.7) nmol/L among women who subsequently developed myocardial infarction and 16.6 (6.1, 37.9) among controls. The risk of myocardial infarction increased with plasma concentrations of DHEA and its sulfate. Women in the highest DHEA quartile had a rate ratio (RR) of 1.27 (95% CI 0.92-1.74, P for trend = 0.008) for myocardial infarction compared with those in the lowest quartile, after adjusting for covariates. The results did not vary significantly by menopausal status, postmenopausal estrogen therapy, fasting status, or age at time of blood collection. Similar relationships between concentrations of DHEA-S and risk were observed, with an RR of 1.58 (95% CI 1.13-2.21; P for trend = 0.06) for myocardial infarction in the highest vs lowest quartile.

Conclusions: We observed a modest positive relationship between plasma concentrations of DHEA and its sulfate and the risk of subsequent myocardial infarction among predominantly postmenopausal women.

Citing Articles

Low Serum Dehydroepiandrosterone and Dehydroepiandrosterone Sulfate Are Associated With Coronary Heart Disease in Men With Type 2 Diabetes Mellitus.

Zhang X, Xiao J, Liu T, He Q, Cui J, Tang S Front Endocrinol (Lausanne). 2022; 13:890029.

PMID: 35832423 PMC: 9271610. DOI: 10.3389/fendo.2022.890029.

Dehydroepiandrosterone on metabolism and the cardiovascular system in the postmenopausal period.

Jordao Teixeira C, Veras K, Carvalho C J Mol Med (Berl). 2019; 98(1):39-57.

PMID: 31713639 DOI: 10.1007/s00109-019-01842-5.

The relation of telomere length at midlife to subsequent 20-year depression trajectories among women.

Gillis J, Chang S, Wang W, Simon N, Normand S, Rosner B Depress Anxiety. 2019; 36(6):565-575.

PMID: 30958913 PMC: 6548605. DOI: 10.1002/da.22892.

Cardiovascular Risk Factors and Dehydroepiandrosterone Sulfate Among Latinos in the Boston Puerto Rican Health Study.

Jimenez M, Tucker K, Rodriguez F, Porneala B, Meigs J, Lopez L J Endocr Soc. 2019; 3(1):291-303.

PMID: 30623167 PMC: 6320241. DOI: 10.1210/js.2018-00205.

Longitudinal associations of lifetime adiposity with leukocyte telomere length and mitochondrial DNA copy number.

Hang D, Nan H, Kvaerner A, De Vivo I, Chan A, Hu Z Eur J Epidemiol. 2018; 33(5):485-495.

PMID: 29619669 PMC: 8063494. DOI: 10.1007/s10654-018-0382-z.

References

Sugiuchi H, Uji Y, Okabe H, Irie T, Uekama K, Kayahara N . Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated alpha-cyclodextrin. Clin Chem. 1995; 41(5):717-23. View

Labrie F, Luu-The V, Labrie C, Simard J . DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology. Front Neuroendocrinol. 2001; 22(3):185-212. DOI: 10.1006/frne.2001.0216. View

Barrett-Connor E . Dehydroepiandrosterone sulfate does not predict cardiovascular death in postmenopausal women. The Rancho Bernardo Study. Circulation. 1995; 91(6):1757-60. DOI: 10.1161/01.cir.91.6.1757. View

Hankinson S, London S, Chute C, Barbieri R, Jones L, Kaplan L . Effect of transport conditions on the stability of biochemical markers in blood. Clin Chem. 1989; 35(12):2313-6. View

Herrington D, Gordon G, Achuff S, Trejo J, Weisman H, Kwiterovich Jr P . Plasma dehydroepiandrosterone and dehydroepiandrosterone sulfate in patients undergoing diagnostic coronary angiography. J Am Coll Cardiol. 1990; 16(6):862-70. DOI: 10.1016/s0735-1097(10)80334-1. View

Liu P, Death A, Handelsman D . Androgens and cardiovascular disease. Endocr Rev. 2003; 24(3):313-40. DOI: 10.1210/er.2003-0005. View

Ciaraldi T, Madar Z, Reichart D, Olefsky J, Yen S . Cellular mechanisms of insulin resistance in polycystic ovarian syndrome. J Clin Endocrinol Metab. 1992; 75(2):577-83. DOI: 10.1210/jcem.75.2.1322430. View

ALLAIN C, Poon L, Chan C, Richmond W, Fu P . Enzymatic determination of total serum cholesterol. Clin Chem. 1974; 20(4):470-5. View

Nair K, Rizza R, OBrien P, Dhatariya K, Short K, Nehra A . DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med. 2006; 355(16):1647-59. DOI: 10.1056/NEJMoa054629. View

10.

Villareal D, Holloszy J . Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial. JAMA. 2004; 292(18):2243-8. DOI: 10.1001/jama.292.18.2243. View

11.

Skolnick A . Scientific verdict still out on DHEA. JAMA. 1996; 276(17):1365-7. View

12.

Nawata H, Yanase T, Goto K, Okabe T, Ashida K . Mechanism of action of anti-aging DHEA-S and the replacement of DHEA-S. Mech Ageing Dev. 2002; 123(8):1101-6. DOI: 10.1016/s0047-6374(01)00393-1. View

13.

Haning Jr R, Austin C, CARLSON I, Kuzma D, Zweibel W . Role of dehydroepiandrosterone sulfate as a prehormone for ovarian steroidogenesis. Obstet Gynecol. 1985; 65(2):199-205. View

14.

Rexrode K, Manson J, Lee I, Ridker P, Sluss P, Cook N . Sex hormone levels and risk of cardiovascular events in postmenopausal women. Circulation. 2003; 108(14):1688-93. DOI: 10.1161/01.CIR.0000091114.36254.F3. View

15.

Ding E, Song Y, Manson J, Rifai N, Buring J, Liu S . Plasma sex steroid hormones and risk of developing type 2 diabetes in women: a prospective study. Diabetologia. 2007; 50(10):2076-84. DOI: 10.1007/s00125-007-0785-y. View

16.

Barrett-Connor E, Khaw K, Yen S . A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med. 1986; 315(24):1519-24. DOI: 10.1056/NEJM198612113152405. View

17.

Barrett-Connor E, Ferrara A . Dehydroepiandrosterone, dehydroepiandrosterone sulfate, obesity, waist-hip ratio, and noninsulin-dependent diabetes in postmenopausal women: the Rancho Bernardo Study. J Clin Endocrinol Metab. 1996; 81(1):59-64. DOI: 10.1210/jcem.81.1.8550794. View

18.

Page J, Colditz G, Rifai N, Barbieri R, Willett W, Hankinson S . Plasma adrenal androgens and risk of breast cancer in premenopausal women. Cancer Epidemiol Biomarkers Prev. 2004; 13(6):1032-6. View

19.

Kroboth P, Salek F, Pittenger A, Fabian T, Frye R . DHEA and DHEA-S: a review. J Clin Pharmacol. 1999; 39(4):327-48. DOI: 10.1177/00912709922007903. View

20.

Ebeling P, Koivisto V . Physiological importance of dehydroepiandrosterone. Lancet. 1994; 343(8911):1479-81. DOI: 10.1016/s0140-6736(94)92587-9. View